• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Thalidomide shows efficacy as a potential anti-tussive for idiopathic pulmonary fibrosis

bys25qthea
September 25, 2012
in Chronic Disease, Pulmonology
Reading Time: 5 mins read
0
Share on FacebookShare on Twitter

Image: CC/P.Path

Key study points:

1.       Thalidomide treatment improved cough-specific quality of life and decreased cough severity in IPF patients compared to placebo treatment

2.       Thalidomide also improved overall respiratory quality of life in IPF patients compared to placebo.

3.       Patients receiving thalidomide demonstrated an increased risk of adverse events when compared to controls.

Primer: Idiopathic Pulmonary Fibrosis (IPF) is a disease that affects over 40 persons per 100000 people with no definitive treatment or cure and a median survival of 3-5 years after diagnosis.

RELATED REPORTS

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

Evaluating scar outcomes in pediatric burn patients following skin grafting 

Among patients suffering from IPF, cough is one of the most common symptoms reported. Studies have demonstrated that not only is non-productive, persistent cough incredibly distressing and disabling to patients, but it has been found to be an independent predictor of disease progression and outcomes (time to death or lung transplant). Unfortunately, typical cough-suppressing treatments such as opiods and topical airway analgesics have been largely ineffective in the treatment of IPF-related cough.

Immune dysregulation has long been considered to play a major role in disease pathogenesis and immunosuppressive medications have been a mainstay of IPF therapy. Recent studies looking at immunomodulators, such as interferon-alpha and thalidomide, for the treatment of IPF have noted that these drugs may have some effect in improving cough symptoms. In an effort to more specifically investigate the efficacy of thalidomide in the treatment of IPF-related cough, researchers at the Johns Hopkins University School of Medicine designed and conducted this clinical trial.

See Also:
–          Idiopathic Pulmonary Fibrosis [NEJM]
–          Cough predicts prognosis in idiopathic pulmonary fibrosis [Respirology]
–          Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis [Thorax]
 

This [double-blinded, placebo-controlled crossover] trial: 24 patients were randomized receive thalidomide (n=12) or placebo (n=12). The first treatment period lasted for a total of 12 weeks and was then followed by a 2 week washout period before the groups were crossed over for the second 12-week treatment period. During each treatment period, patients were initially given a 50mg dose of the medication (thalidomide or placebo) and this dose was increased to 100mg if no improvement in cough occurred by week 2. Treatment efficacy was evaluated via the Cough Quality of Life Questionnaire (CQLQ), which looked at cough-related quality of life, a visual analog scale, which calculated cough severity, and the St. George’s Respiratory Questionnaire, which measured respiratory quality of life. Statistical analysis revealed several key findings:

–          Patients receiving thalidomide demonstrated a significant decrease in the effect of cough on quality of life compared to placebo, with a mean difference in CQLQ score of 11.4 (CI: -15.7 to -7.0)
–          Patients receiving thalidomide demonstrated a significant decrease in cough severity with a mean difference of 31.2 (CI: -45.2 to -17.2) compared to placebo.
–          Patients receiving thalidomide reported a significantly improvement in respiratory quality of life compared to placebo, with a mean difference of 11.7 (CI: -18.6 to -4.8) compared to placebo.
–          Significantly more adverse events (77% versus 22%, p=0.001), particularly constipation and bradycardia, were reported among patients receiving thalidomide.
 

In sum: The authors conclude that this study demonstrates “low dose thalidomide not only significantly improves cough in patients with IPF, as evidence by the improvement in CQLQ and visual analog scale scores, but also improves overall quality of life.”

However, the study does face some limitations. First, given the small number of participants and the single site studied, the results may not by representative of the whole patient population. Second, there was greater loss to follow up in the thalidomide group than in the control group, a potential source of bias, which the authors accounted for with sensitivity analysis. Third, the study duration of 3 months was relatively short and thus further study is needed to understand the long-term efficacy and adverse event profile of thalidomide treatment for IPF-related cough.  Fourth, while the study was double-blinded, thalidomide’s unique side effect profile may have allowed some participants to identify the drug and thus introduce bias in their response and/or reports, a possibility that the authors did not address in their study. Finally, general health-related quality of life was not assessed and thus the effective of thalidomide side effects on overall health was not weighed against its effects on cough and respiratory quality of life. However, as all participants requested thalidomide when given the option at the end of the study, despite adverse outcomes experienced, the authors concluded that thalidomide’s benefits likely outweighed its side effects.

This study is the first clinical trial demonstrating efficacy in a treatment for IPF-related cough. The authors propose that a large-scale, multi-center trial would be the best next step in evaluating the long-term efficacy and safety of thalidomide in treating cough in IPF.

Click to read the study in Annals of Internal Medicine

By MK

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. DISCALIMER: Posts are not medical advice and are not intended as such. Please see a healthcare professional if you seek medical advice.

Previous Post

Sugar-free beverages significantly reduce weight gain in children

Next Post

Post-operative mortality rates higher than expected across 28 European nations

RelatedReports

Chronic Disease

Weighted vests and resistance training confer similar outcomes for bone density in the elderly

June 27, 2025
AI Roundup

Breast cancer survivors may have a lower risk of Alzheimer’s dementia

June 26, 2025
Pediatrics

Evaluating scar outcomes in pediatric burn patients following skin grafting 

June 26, 2025
PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study
Cardiology

Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans

June 26, 2025
Next Post

Post-operative mortality rates higher than expected across 28 European nations

Moderate chocolate consumption lowers risk of stroke in men

Four different types of breast cancer revealed based on molecular data

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.